StockData
Myriad Genetics Inc logo

Myriad Genetics Inc (MYGN) stock

MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.54−0.03 (-0.54%)

Close on Nov 17, 2026Market cap $529.90MP/E –Yield –

Myriad Genetics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Myriad Genetics's enterprise value was $552.33M on Nov 11, 2026, against $684.45M a year earlier. Over the last 5 years it ranged from $265.88M to $2.52B, with a median of $1.37B.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$552.33M+1.0%
2025Dec 31, 2025$546.67M-53.9%
2024Dec 31, 2024$1.19B-22.1%
2023Dec 29, 2023$1.52B+55.0%
2022Dec 30, 2022$982.66M-51.6%
2021Dec 31, 2021$2.03B+40.4%
2020Dec 31, 2020$1.45B-31.4%
2019Dec 31, 2019$2.11B-6.8%
2018Dec 31, 2018$2.26B+1.5%
2017Dec 29, 2017$2.23B+87.1%
2016Dec 30, 2016$1.19B-58.1%
2015Dec 31, 2015$2.84B+22.1%
2014Dec 31, 2014$2.33B+85.5%
2013Dec 31, 2013$1.25B-32.9%
2012Dec 31, 2012$1.87B+31.4%
2011Dec 30, 2011$1.42B-15.4%
2010Dec 31, 2010$1.68B-33.0%
2009Dec 31, 2009$2.51B–

More Myriad Genetics figures

See a number that looks wrong?